These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 7609139)

  • 1. Interleukin-6 production by bladder tumors is upregulated by BCG immunotherapy.
    Esuvaranathan K; Alexandroff AB; McIntyre M; Jackson AM; Prescott S; Chisholm GD; James K
    J Urol; 1995 Aug; 154(2 Pt 1):572-5. PubMed ID: 7609139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of bacillus Calmette-Guèrin and interferon alpha-2B on cytokine production in human bladder cancer cell lines.
    Zhang Y; Khoo HE; Esuvaranathan K
    J Urol; 1999 Mar; 161(3):977-83. PubMed ID: 10022737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Localization of IL-1, IL-2, IL-4, IL-8 and TNF in superficial bladder tumors treated with intravesical bacillus Calmette-Guerin.
    Sander B; Damm O; Gustafsson B; Andersson U; Håkansson L
    J Urol; 1996 Aug; 156(2 Pt 1):536-41. PubMed ID: 8683732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BCG-induced interleukin-6 upregulation and BCG internalization in well and poorly differentiated human bladder cancer cell lines.
    Bevers RF; de Boer EC; Kurth KH; Schamhart DH
    Eur Cytokine Netw; 1998 Jun; 9(2):181-6. PubMed ID: 9681394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravesical bacille Calmette-Guérin induces the antiangiogenic chemokine interferon-inducible protein 10.
    Poppas DP; Pavlovich CP; Folkman J; Voest EE; Chen X; Luster AD; O'Donnell MA
    Urology; 1998 Aug; 52(2):268-75; discussion 275-6. PubMed ID: 9697793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
    Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
    J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urinary interleukin-8 levels are elevated in subjects with transitional cell carcinoma.
    Sheryka E; Wheeler MA; Hausladen DA; Weiss RM
    Urology; 2003 Jul; 62(1):162-6. PubMed ID: 12837459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin.
    Thalmann GN; Sermier A; Rentsch C; Möhrle K; Cecchini MG; Studer UE
    J Urol; 2000 Dec; 164(6):2129-33. PubMed ID: 11061941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression and shedding of ICAM-1 in bladder cancer and its immunotherapy.
    Jackson AM; Alexandrov AB; Gribben SC; Esuvarnathan K; James K
    Int J Cancer; 1993 Dec; 55(6):921-5. PubMed ID: 7902828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of interleukin 2 in the urine of patients with superficial bladder tumors after treatment with intravesical BCG.
    Haaff EO; Catalona WJ; Ratliff TL
    J Urol; 1986 Oct; 136(4):970-4. PubMed ID: 3489840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BCG immunotherapy for transitional-cell carcinoma in situ of the bladder.
    Lamm DL
    Oncology (Williston Park); 1995 Oct; 9(10):947-52, 955, discussion 955-65. PubMed ID: 8573479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value.
    de Reijke TM; de Boer EC; Kurth KH; Schamhart DH
    J Urol; 1996 Feb; 155(2):477-82. PubMed ID: 8558640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carcinoma in situ and treatment options.
    Erton M; Ilker Y; Akdaş
    Int Urol Nephrol; 1996; 28(1):33-42. PubMed ID: 8738617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fibronectin expression on surgical specimens correlated with the response to intravesical bacillus Calmette-Guerin therapy.
    Fleischmann JD; Park MC; Hassan MO
    J Urol; 1993 Feb; 149(2):268-71. PubMed ID: 8426398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serial urinary IL-2, IL-6, IL-8, TNFalpha, UBC, CYFRA 21-1 and NMP22 during follow-up of patients with bladder cancer receiving intravesical BCG.
    Sanchez-Carbayo M; Urrutia M; Romani R; Herrero M; Gonzalez de Buitrago JM; Navajo JA
    Anticancer Res; 2001; 21(4B):3041-7. PubMed ID: 11712808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Urethral recurrence of invasive carcinoma following BCG treatment for bladder Ca in situ].
    Ruoppolo M; Gozo M; Milesi R; Spina R; Fragapane G
    Urologia; 2010; 77 Suppl 17():72-7. PubMed ID: 21308679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after bacillus Calmette-Guérin (BCG) immunotherapy.
    Jackson AM; Alexandroff AB; Kelly RW; Skibinska A; Esuvaranathan K; Prescott S; Chisholm GD; James K
    Clin Exp Immunol; 1995 Mar; 99(3):369-75. PubMed ID: 7882559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.
    Dowell AC; Cobby E; Wen K; Devall AJ; During V; Anderson J; James ND; Cheng KK; Zeegers MP; Bryan RT; Taylor GS
    PLoS One; 2017; 12(9):e0184841. PubMed ID: 28931051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic problems of urine cytology on initial follow-up after intravesical immunotherapy with Calmette-Guérin bacillus for superficial bladder cancer.
    Mack D; Frick J
    Urol Int; 1994; 52(4):204-7. PubMed ID: 8030167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Importance of urinary interleukin-18 in intravesical immunotherapy with bacillus calmette-guérin for superficial bladder tumors.
    Eto M; Koga H; Noma H; Yamaguchi A; Yoshikai Y; Naito S
    Urol Int; 2005; 75(2):114-8. PubMed ID: 16123563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.